Manuscript
Risk factors for bone fractures in type 2 diabetes and the impact of once-weekly exenatide: Insights from an EXSCEL post-hoc analysis
Erenesto Maddaloni et al.
Diabetes Res Clin Pract. 2025;223:112125
Manuscript
Response to Comments on Maddaloni et al. Osteoprotegerin, Osteopontin, and Osteocalcin Are Associated With Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. Diabetes Care 2025;48:235-242
Ernesto Maddaloni et al.
Diabetes Care 2025;48:e61-e62
Manuscript
Identification of plasma proteomic markers underlying polygenic risk of type 2 diabetes and related comorbidities
Loesch DP et al.
Nat Commun. 2025;16:2124
Manuscript
A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation study
John M Dennis et al.
Lancet 2025;405:701-714
Manuscript
Cardiovascular Outcomes with Exenatide in Type 2 Diabetes according to Ejection Fraction: the EXSCEL trial
João Sérgio Neves et al.
Eur J Heart Fail 2025;27:540-551
Manuscript
Osteoprotegerin, Osteopontin, and Osteocalcin Are Associated With Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL
Erenesto Maddaloni et al.
Diabetes Care 2025;48:235-242